CA2465731A1 - Screening for hepatitis c virus entry inhibitors - Google Patents

Screening for hepatitis c virus entry inhibitors Download PDF

Info

Publication number
CA2465731A1
CA2465731A1 CA002465731A CA2465731A CA2465731A1 CA 2465731 A1 CA2465731 A1 CA 2465731A1 CA 002465731 A CA002465731 A CA 002465731A CA 2465731 A CA2465731 A CA 2465731A CA 2465731 A1 CA2465731 A1 CA 2465731A1
Authority
CA
Canada
Prior art keywords
hcv
binding
cell
polypeptide
functional derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465731A
Other languages
English (en)
French (fr)
Inventor
Riccardo Cortese
Elisa Scarselli
Alessandra Vitelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2465731A1 publication Critical patent/CA2465731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002465731A 2001-11-09 2002-11-01 Screening for hepatitis c virus entry inhibitors Abandoned CA2465731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34450401P 2001-11-09 2001-11-09
US60/344,504 2001-11-09
PCT/EP2002/012272 WO2003040726A2 (en) 2001-11-09 2002-11-01 Screening for hepatitis c virus entry inhibitors

Publications (1)

Publication Number Publication Date
CA2465731A1 true CA2465731A1 (en) 2003-05-15

Family

ID=23350803

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465731A Abandoned CA2465731A1 (en) 2001-11-09 2002-11-01 Screening for hepatitis c virus entry inhibitors

Country Status (7)

Country Link
US (1) US20050019751A1 (enExample)
EP (1) EP1444523B1 (enExample)
JP (1) JP2005509160A (enExample)
AT (1) ATE491952T1 (enExample)
CA (1) CA2465731A1 (enExample)
DE (1) DE60238633D1 (enExample)
WO (1) WO2003040726A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021203828A1 (zh) * 2020-04-09 2021-10-14 中国人民解放军军事科学院军事医学研究院 一种抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
EP1765869B1 (en) * 2004-07-08 2015-05-20 JV Bio S.r.l Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication
WO2006103493A1 (en) * 2005-03-29 2006-10-05 Epixis Methods for enhancing the potency of hcv neutralizing antibodies
EP1991215A1 (en) * 2006-03-09 2008-11-19 Cenix Bioscience GmbH Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
EP1832283A1 (en) * 2006-03-09 2007-09-12 Cenix Bioscience GmbH Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
US9052321B2 (en) * 2008-10-03 2015-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flavivirus-based system for production of hepatitis C virus (HCV)
CN108349853B (zh) * 2015-11-12 2022-03-15 沙特基础工业全球技术公司 生产芳烃和烯烃的方法
JP2025531751A (ja) * 2022-09-07 2025-09-25 ユナイテッド キングダム リサーチ アンド イノベーション 代謝関連疾患のための治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5998141A (en) * 1997-07-10 1999-12-07 Millennium Pharmaceuticals, Inc. Intronic and polymorphic SR-BI nucleic acids and uses therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021203828A1 (zh) * 2020-04-09 2021-10-14 中国人民解放军军事科学院军事医学研究院 一种抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用

Also Published As

Publication number Publication date
EP1444523B1 (en) 2010-12-15
WO2003040726A3 (en) 2003-12-18
DE60238633D1 (de) 2011-01-27
US20050019751A1 (en) 2005-01-27
WO2003040726A2 (en) 2003-05-15
ATE491952T1 (de) 2011-01-15
JP2005509160A (ja) 2005-04-07
EP1444523A2 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
Gao et al. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft
Saunier et al. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes
Hamamoto et al. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B
Yu et al. Palmitoylation and polymerization of hepatitis C virus NS4B protein
Scarselli et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
Aizaki et al. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts
Berger et al. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus–induced membranous replication factories, independent of RNA replication
Okamoto et al. Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation
Wang et al. Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells
US7446177B2 (en) Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
Johnson et al. Functional and therapeutic analysis of hepatitis C virus NS3· 4A protease control of antiviral immune defense
Zhu et al. Significance of palmitoylation of CD81 on its association with tetraspanin-enriched microdomains and mediating hepatitis C virus cell entry
Okamoto et al. A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication
Wu et al. Palmitoylation of hepatitis C virus NS2 regulates its subcellular localization and NS2-NS3 autocleavage
EP1444523B1 (en) Screening for hepatitis c virus entry inhibitors
Georgopoulou et al. The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein
Wu et al. Isoform-specific interaction of pyruvate kinase with hepatitis C virus NS5B
Choi et al. A hepatitis C virus NS4B inhibitor suppresses viral genome replication by disrupting NS4B’s dimerization/multimerization as well as its interaction with NS5A
Zhang et al. Differences in membrane association and sub-cellular distribution between NS2-3 and NS3 of bovine viral diarrhoea virus
Liefhebber et al. Hepatitis C virus NS4B carboxy terminal domain is a membrane binding domain
Fenouillet et al. Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity
JP2006512077A (ja) Ｃ型肝炎ウイルスの感染を阻害するための、ｄｃ−ｓｉｇｎおよびｄｃ−ｓｉｇｎｒの使用
EP1946770A1 (en) Uses of DC-sign and DC-signr for inhibiting hepatitis C virus infection
Jia et al. Scavenger receptor class B type I mediates cell entry of hepatitis C virus
Tamura et al. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued